Literature DB >> 21901672

RNA aptamers and spiegelmers: synthesis, purification, and post-synthetic PEG conjugation.

Stefanie Hoffmann1, Johannes Hoos, Sven Klussmann, Stefan Vonhoff.   

Abstract

This unit describes the solid-phase synthesis and downstream processing for RNA oligonucleotides with a length of up to 40 to 50 nucleotides on a 1- to 4-mmol scale with subsequent conjugation to PEG using the L-RNA spiegelmer NOX-E36 as an example. Following synthesis and two-step deprotection, the crude oligonucleotide is purified by preparative reversed-phase HPLC and desalted by tangential flow ultrafiltration. The resulting intermediate amino-modified oligonucleotide is reacted with NHS-ester-activated PEG, and the oligonucleotide-PEG conjugate is obtained after preparative AX-HPLC purification, followed by ultrafiltration and lyophilization. Critical process parameters are described, as well as time considerations and examples for analytical methods used as in-process and quality controls.
© 2011 by John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21901672     DOI: 10.1002/0471142700.nc0446s46

Source DB:  PubMed          Journal:  Curr Protoc Nucleic Acid Chem        ISSN: 1934-9270


  21 in total

1.  A novel C5a-neutralizing mirror-image (l-)aptamer prevents organ failure and improves survival in experimental sepsis.

Authors:  Kai Hoehlig; Christian Maasch; Nelli Shushakova; Klaus Buchner; Markus Huber-Lang; Werner G Purschke; Axel Vater; Sven Klussmann
Journal:  Mol Ther       Date:  2013-07-26       Impact factor: 11.454

2.  The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization.

Authors:  Julia Hoellenriegel; Dirk Zboralski; Christian Maasch; Nathalie Y Rosin; William G Wierda; Michael J Keating; Anna Kruschinski; Jan A Burger
Journal:  Blood       Date:  2013-11-25       Impact factor: 22.113

3.  SDF-1 inhibition targets the bone marrow niche for cancer therapy.

Authors:  Aldo M Roccaro; Antonio Sacco; Werner G Purschke; Michele Moschetta; Klaus Buchner; Christian Maasch; Dirk Zboralski; Stefan Zöllner; Stefan Vonhoff; Yuji Mishima; Patricia Maiso; Michaela R Reagan; Silvia Lonardi; Marco Ungari; Fabio Facchetti; Dirk Eulberg; Anna Kruschinski; Axel Vater; Giuseppe Rossi; Sven Klussmann; Irene M Ghobrial
Journal:  Cell Rep       Date:  2014-09-25       Impact factor: 9.423

Review 4.  Therapeutic nucleic acids: current clinical status.

Authors:  Kannan Sridharan; Nithya Jaideep Gogtay
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

5.  A novel CGRP-neutralizing Spiegelmer attenuates neurogenic plasma protein extravasation.

Authors:  K Hoehlig; K W Johnson; E Pryazhnikov; C Maasch; A Clemens-Smith; W G Purschke; S Vauléon; K Buchner; F Jarosch; L Khiroug; A Vater; S Klussmann
Journal:  Br J Pharmacol       Date:  2015-03-27       Impact factor: 8.739

Review 6.  Mirror-Image Oligonucleotides: History and Emerging Applications.

Authors:  Brian E Young; Nandini Kundu; Jonathan T Sczepanski
Journal:  Chemistry       Date:  2019-04-26       Impact factor: 5.236

7.  The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys.

Authors:  Frank Schwoebel; Lucas T van Eijk; Dirk Zboralski; Simone Sell; Klaus Buchner; Christian Maasch; Werner G Purschke; Martin Humphrey; Stefan Zöllner; Dirk Eulberg; Frank Morich; Peter Pickkers; Sven Klussmann
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

8.  Optimization of N-hydroxysuccinimide ester coupling with aminoallyl-modified RNA for fluorescent labeling.

Authors:  Mengyang Li
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

9.  Trial Watch: Immunostimulatory cytokines.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Jerome Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-07-01       Impact factor: 8.110

10.  Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2.

Authors:  Dominik Oberthür; John Achenbach; Azat Gabdulkhakov; Klaus Buchner; Christian Maasch; Sven Falke; Dirk Rehders; Sven Klussmann; Christian Betzel
Journal:  Nat Commun       Date:  2015-04-22       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.